Literature DB >> 12938165

Differentiation potential of a mouse bone marrow stromal cell line.

Elizabeth H Allan1, Patricia W M Ho, Akihro Umezawa, Jun-Ichi Hata, Fusao Makishima, Matthew T Gillespie, T John Martin.   

Abstract

In order to study osteoblast differentiation we subcloned a cell derived from a mouse a bone marrow stromal cell line, Kusa O, and obtained a number of clones representative of three different phenotypes. One that neither differentiated into osteoblasts nor into adipocytes, a second that differentiated into osteoblasts but not adipocytes, and a third that differentiated into both osteoblasts and adipocytes. Four subclones were selected for further characterization according to their ability to mineralize and/or differentiate into adipocytes. The non-mineralizing clone had no detectable alkaline phosphatase activity although some alkaline phosphatase mRNA was detected after 21 days in osteoblast differentiating medium. Alkaline phosphatase activity and mRNA in the three mineralizing clones were comparable with the parent clones. Osteocalcin mRNA and protein levels in the non-mineralizing clone were low and non-detectable, respectively, while both were elevated in the parent cells and mineralizing subclones after 21 days in differentiating medium. PTH receptor mRNA and activity increased in the four subclones and parent cells with differentiation. mRNA for two other osteoblast phenotypic markers, osteopontin and bone sialoprotein, were similarly expressed in the parent cells and subclones while mRNAs for the transcription factors, Runx2 and osterix, were detectable in both parent and subclone cells. Runx2 was unchanged with differentiation while osterix was increased. Interestingly, PPARgamma mRNA expression did not correlate with cell line potential to differentiate into adipocytes. Indian hedgehog mRNA and its receptor (patched) mRNA levels both increased with differentiation while mRNA levels of the Wnt pathway components beta-catenin and dickkopf also increased with differentiation. Although we have focussed on characterizing these clones from the osteoblast perspective it is clear that they may be useful for studying both osteoblast and adipocyte differentiation as well as their transdifferentiation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938165     DOI: 10.1002/jcb.10614

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  29 in total

1.  Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes.

Authors:  Xin-Qin Kang; Wei-Jin Zang; Li-Jun Bao; Dong-Ling Li; Tu-Sheng Song; Xiao-Li Xu; Xiao-Jiang Yu
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

2.  Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function.

Authors:  Julian M W Quinn; Shanna Tam; Natalie A Sims; Hasnawati Saleh; Narelle E McGregor; Ingrid J Poulton; John W Scott; Matthew T Gillespie; Bruce E Kemp; B J W van Denderen
Journal:  FASEB J       Date:  2009-09-01       Impact factor: 5.191

3.  EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase.

Authors:  Shek Man Chim; An Qin; Jennifer Tickner; Nathan Pavlos; Tamara Davey; Hao Wang; Yajun Guo; Ming Hao Zheng; Jiake Xu
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

4.  IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis.

Authors:  Narelle E McGregor; Melissa Murat; Jeevithan Elango; Ingrid J Poulton; Emma C Walker; Blessing Crimeen-Irwin; Patricia W M Ho; Jonathan H Gooi; T John Martin; Natalie A Sims
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

5.  HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR.

Authors:  Kavita Bisht; Marion E Brunck; Taichi Matsumoto; Crystal McGirr; Bianca Nowlan; Whitney Fleming; Thomas Keech; Graham Magor; Andrew C Perkins; Julie Davies; Gail Walkinshaw; Lee Flippin; Ingrid G Winkler; Jean-Pierre Levesque
Journal:  Blood Adv       Date:  2019-02-12

6.  Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats.

Authors:  Dongliang Li; Jingjing Fan; Xiuhua He; Xia Zhang; Zhiqiang Zhang; Zhiyu Zeng; Mei Ruan; Lirong Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

7.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.

Authors:  Emma C Walker; Narelle E McGregor; Ingrid J Poulton; Melissa Solano; Sueli Pompolo; Tania J Fernandes; Matthew J Constable; Geoff C Nicholson; Jian-Guo Zhang; Nicos A Nicola; Matthew T Gillespie; T John Martin; Natalie A Sims
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

8.  Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.

Authors:  Vicky Kartsogiannis; Natalie A Sims; Julian M W Quinn; Chi Ly; Mirijana Cipetic; Ingrid J Poulton; Emma C Walker; Hasnawati Saleh; Narelle E McGregor; Morgan E Wallace; Mark J Smyth; T John Martin; Hong Zhou; Kong Wah Ng; Matthew T Gillespie
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

Review 9.  Primary cilia and signaling pathways in mammalian development, health and disease.

Authors:  Iben R Veland; Aashir Awan; Lotte B Pedersen; Bradley K Yoder; Søren T Christensen
Journal:  Nephron Physiol       Date:  2009-03-10

10.  CCN3 and bone marrow cells.

Authors:  Ken-Ichi Katsube; Saki Ichikawa; Yuko Katsuki; Tasuku Kihara; Masanori Terai; Lester F Lau; Yoshihiro Tamamura; Shin'ichi Takeda; Akihiro Umezawa; Kei Sakamoto; Akira Yamaguchi
Journal:  J Cell Commun Signal       Date:  2009-07-23       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.